Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ] - Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012
Fri, July 6, 2012
Thu, July 5, 2012
Wed, July 4, 2012
[ Wed, Jul 04th 2012 ] - Market Wire
Warnex Announces Refinancing
Tue, July 3, 2012
Mon, July 2, 2012
Sun, July 1, 2012
Fri, June 29, 2012
Thu, June 28, 2012
Wed, June 27, 2012
Tue, June 26, 2012

AVI BioPharma to Present Company Overview at the Seventh Annual JMP Securities Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. annual-jmp-securities-healthcare-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


July 06, 2012 16:05 ET

AVI BioPharma to Present Company Overview at the Seventh Annual JMP Securities Healthcare Conference

Webcast Accessible via AVI Website

BOTHELL, WA--(Marketwire - Jul 6, 2012) - AVI BioPharma, Inc. (NASDAQ: [ AVII ]), a developer of RNA-based therapeutics, announced today that it is scheduled to present at the Seventh Annual JMP Securities Healthcare Conference in New York, NY on Thursday, July 12, at 1:30 p.m. Eastern Time. Chris Garabedian, AVI's President and CEO, will be the presenter.

The presentation will be webcast live under the events section of AVI's website at [ www.avibio.com ] and will be archived there following the presentation for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy, and multiple drug candidates that are in clinical development for the treatment of infectious disease. For more information, please visit [ www.avibio.com ].



Publication Contributing Sources